S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Allena Pharmaceuticals (NASDAQ:ALNA) Lowered to "Hold" at Zacks Investment Research

Friday, January 14, 2022 | MarketBeat

Allena Pharmaceuticals (NASDAQ:ALNA) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. "

Allena Pharmaceuticals stock traded down $0.02 during midday trading on Friday, reaching $0.45. 25,304 shares of the stock were exchanged, compared to its average volume of 3,340,494. The company's fifty day moving average is $0.68 and its 200-day moving average is $0.87. The company has a debt-to-equity ratio of 0.38, a quick ratio of 5.47 and a current ratio of 5.47. The firm has a market cap of $36.83 million, a PE ratio of -0.52 and a beta of 2.04. Allena Pharmaceuticals has a 52 week low of $0.46 and a 52 week high of $2.78.

Allena Pharmaceuticals (NASDAQ:ALNA) last issued its quarterly earnings results on Wednesday, November 10th. The company reported ($0.17) EPS for the quarter, topping the Zacks' consensus estimate of ($0.18) by $0.01. On average, sell-side analysts anticipate that Allena Pharmaceuticals will post -0.76 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. Altium Capital Management LP purchased a new stake in shares of Allena Pharmaceuticals in the 3rd quarter valued at $963,000. Vanguard Group Inc. boosted its stake in shares of Allena Pharmaceuticals by 70.2% in the 2nd quarter. Vanguard Group Inc. now owns 1,961,144 shares of the company's stock valued at $2,549,000 after purchasing an additional 809,035 shares in the last quarter. Morgan Stanley boosted its stake in shares of Allena Pharmaceuticals by 63.9% in the 2nd quarter. Morgan Stanley now owns 1,045,481 shares of the company's stock valued at $1,359,000 after purchasing an additional 407,599 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Allena Pharmaceuticals by 44.2% in the 2nd quarter. Renaissance Technologies LLC now owns 700,601 shares of the company's stock valued at $911,000 after purchasing an additional 214,671 shares in the last quarter. Finally, GSA Capital Partners LLP purchased a new stake in shares of Allena Pharmaceuticals in the 3rd quarter valued at $138,000. 24.13% of the stock is currently owned by hedge funds and other institutional investors.

Allena Pharmaceuticals Company Profile

Allena Pharmaceuticals, Inc engages in the development, discovery and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease.

Further Reading: Stock Market - What is a circuit breaker?

Get a free copy of the Zacks research report on Allena Pharmaceuticals (ALNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Allena Pharmaceuticals right now?

Before you consider Allena Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allena Pharmaceuticals wasn't on the list.

While Allena Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.